CA-ULTRAVIOLET-DEVICES
14.1.2021 14:47:33 CET | Business Wire | Press release
UltraViolet Devices, Inc. (UVDI) announced its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10 , inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters). Testing on the coronavirus strain that causes the COVID-19 disease was conducted by Innovative Bioanalysis, a CAP, CLIA, and BEI-recognized BSL-3 certified laboratory (CA, USA). The Centers for Disease Control and Prevention (CDC) has indicated that the COVID-19 disease can be spread by both surface and airborne transmission of SARS-CoV-2.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005585/en/
The testing parameters were carefully selected to be indicative of rapid whole room disinfection in hospitals. The UVDI-360 Room Sanitizer has previously been proven to help prevent Healthcare-Associated Infections and to inactivate over 35 pathogens, including human coronavirus (229E), in over 10 peer-reviewed published clinical studies and independent laboratory testing.
“We hope this important testing can lend confidence and comfort to Healthcare professionals working bravely and tirelessly to beat COVID-19.” stated Peter Veloz, Chief Executive Officer, UVDI. “Specific to use in hospitals for whole room disinfection, we believe that proving rapid inactivation of pathogens at distances of 8 feet (2.44 meters) and 12 feet (3.65 meters) is the best marker for in-facility performance. Independent confirmation of effectiveness against high-risk pathogens is a common sense, yet critical step to verify disinfecting claims for UV devices.”
“Building on our deep science-based evidence demonstrating the UVDI-360’s effectiveness against high-risk pathogens, including coronaviruses, we feel the healthcare professionals we serve globally deserve proof against the specific SARS-CoV-2 viral strain causing COVID-19,” added Dr. Ashish Mathur, Vice President of Innovation and Technology, UVDI.
About UltraViolet Devices, Inc.
UVDI’s Mission is to make a cleaner, safer, and healthier world through advanced UV-C solutions that disinfect the air and surfaces in the environments we live, work, and play in. UVDI designs and manufactures advanced Ultraviolet light solutions in California, applying over 70 years and three generations of family craftsmanship and care. Over 2,000 UVDI-360 Room Sanitizers are used in approximately 1,000 leading hospitals in more than 25 countries, where it has been proven in peer-reviewed, published studies to reduce Healthcare-Associated Infections and inactivate high-risk pathogens. UVDI’s proven Indoor Air Quality solutions are now installed in over 10,000 International commercial sites. UVDI is proud to be a certified Minority Business Enterprise (MBE).
1 https://www.cdc.gov/coronavirus
View source version on businesswire.com: https://www.businesswire.com/news/home/20210114005585/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
